Oculis Holding AG
OCS
NASDAQ·Healthcare·Biotechnology·Mkt cap $695.8M
$12.17
▲ 0.00%
P/E
-7.50
Mkt Cap
$695.8M
52-Wk Range
$10.52–$34.48
52-Week Range
$10.52 - $34.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 29.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+8.6% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OCS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.20 vs -$0.48 consensus (+58.3% surprise). Revenue of $371.1K vs $216.8K expected (+71.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+58.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$325.8K
$303.3K
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jun 11, 2026
vs Industry
How OCS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.